Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.GlobeNewsWire • 01/18/22
Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor EventGlobeNewsWire • 01/06/22
Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance ManagementGlobeNewsWire • 01/03/22
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/09/21
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/11/21
Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/01/21
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewsWire • 09/09/21
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 08/03/21